Abstract
Chemotherapy is the standard monotherapy of Triple Negative Breast Cancer (TNBC) and a main cause for chemo-resistant cases. Anti-programmed death (PDL1) and Anti-Mesothelin (MSLN) therapies has thrust the immunotherapy into spotlight showing a potential cure for TNBC, yet they are understudied. Moreover, MSLN itself was proved to contribute in paclitaxel chemoresistance. MiR-34a along with our previously characterized LncRNA-XIST were proved to be potent tumor-suppressors in TNBC cell lines. This study aims to investigate the role of PD-L1 and MSLN epigenetic regulation in increasing chemo-sensitivity of paclitaxel in TNBC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
